Epidemiology and surveillance of Gram-negative infections caused by carbapenemase-producing organisms (CPOs) in the UK Grant

Epidemiology and surveillance of Gram-negative infections caused by carbapenemase-producing organisms (CPOs) in the UK Grant

Status: ACTIVE
Funder: Pfizer, Inc.
Amount: Up to £50,000
Last Updated: November 25, 2025

Summary

Pfizer is supporting a competitive program focused on the epidemiology and surveillance of Gram-negative infections caused by carbapenemase-producing organisms (CPOs) in the UK. This initiative aims to enhance understanding of patient profiles and the clinical impact of these infections, including the identification of prevalent resistance mechanisms and their effects on antimicrobial susceptibility and treatment protocols. The goal is to improve patient outcomes in this critical area of unmet medical need.

Overview

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Epidemiology and surveillance of Gram-negative infections caused by carbapenemase-producing organisms (CPOs) in the UK Overview This competitive program invites research proposal submissions focussed on improving the understanding of the epidemiology, patient profiles and clinical impact of Gram-negative infections caused by CPOs in the UK including identification of the most prevalent resistance mechanisms and determining their influence on antimicrobial susceptibility, antibiograms and treatment protocols.

Eligibility

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.